GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.

Autor: Galan A; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada., Papaluca A; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada., Nejatie A; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada., Matanes E; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Department of Ob-Gyn, Jewish General Hospital, McGill University and Segal Cancer Center, Lady Davis Institute of Medical Research, Montreal, QC, Canada., Brahimi F; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada., Tong W; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada., Hachim IY; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates., Yasmeen A; Department of Ob-Gyn, Jewish General Hospital, McGill University and Segal Cancer Center, Lady Davis Institute of Medical Research, Montreal, QC, Canada., Carmona E; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du Cancer de Montréal, Montreal, QC, Canada., Klein KO; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Université de Montréal, Montreal, QC, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada., Billes S; R&D Department, AOA Dx Inc, Cambridge, MA, United States., Dawod AE; R&D Department, AOA Dx Inc, Cambridge, MA, United States., Gawande P; R&D Department, AOA Dx Inc, Cambridge, MA, United States., Jeter AM; R&D Department, AOA Dx Inc, Cambridge, MA, United States., Mes-Masson AM; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du Cancer de Montréal, Montreal, QC, Canada.; Department of Medicine, Université de Montréal, Montreal, QC, Canada., Greenwood CMT; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Université de Montréal, Montreal, QC, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada., Gotlieb WH; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Department of Ob-Gyn, Jewish General Hospital, McGill University and Segal Cancer Center, Lady Davis Institute of Medical Research, Montreal, QC, Canada., Saragovi HU; Translational Cancer Center, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, QC, Canada.; Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.; Ophthalmology and Vision Science. McGill University, Montreal, QC, Canada.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Apr 14; Vol. 13, pp. 1134763. Date of Electronic Publication: 2023 Apr 14 (Print Publication: 2023).